Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F.

Ann Oncol. 2014 Mar;25(3):611-8. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Erratum in: Ann Oncol. 2015 Jul;26(7):1518.

2.

Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.

Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, Watanabe G, Tada H, Suzuki A, Ohuchi N, Ishida T.

Breast Cancer Res. 2015 Sep 4;17:124. doi: 10.1186/s13058-015-0632-x.

3.

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.

Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, Goubar A.

Ann Oncol. 2015 Aug;26(8):1698-704. doi: 10.1093/annonc/mdv239. Epub 2015 May 20.

4.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709
5.

Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.

Krishnamurti U, Wetherilt CS, Yang J, Peng L, Li X.

Hum Pathol. 2017 Jun;64:7-12. doi: 10.1016/j.humpath.2017.01.004. Epub 2017 Jan 30.

PMID:
28153508
6.

Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.

Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M.

Anticancer Res. 2018 Apr;38(4):2311-2321.

PMID:
29599354
7.

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH.

Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072. Epub 2011 Dec 8.

8.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.

9.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.

Abdel-Fatah TM, McArdle SE, Agarwal D, Moseley PM, Green AR, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Clin Cancer Res. 2016 Feb 15;22(4):905-14. doi: 10.1158/1078-0432.CCR-15-0610. Epub 2015 Aug 3.

10.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4.

PMID:
18250347
11.

Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.

Lee HJ, Lee JJ, Song IH, Park IA, Kang J, Yu JH, Ahn JH, Gong G.

Breast Cancer Res Treat. 2015 Jun;151(3):619-27. doi: 10.1007/s10549-015-3438-8. Epub 2015 May 26.

PMID:
26006068
12.

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.

Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.

Breast. 2014 Aug;23(4):466-72. doi: 10.1016/j.breast.2014.03.008. Epub 2014 Apr 16.

PMID:
24742606
13.

Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.

Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S, Lucci A.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S552-8. doi: 10.1245/s10434-015-4600-6. Epub 2015 May 13.

PMID:
25968619
14.

Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.

Tomsová M, Melichar B, Sedláková I, Steiner I.

Gynecol Oncol. 2008 Feb;108(2):415-20. Epub 2007 Nov 26.

PMID:
18037158
15.

Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.

Carbognin L, Pilotto S, Nortilli R, Brunelli M, Nottegar A, Sperduti I, Giannarelli D, Bria E, Tortora G.

Oncologist. 2016 Mar;21(3):283-91. doi: 10.1634/theoncologist.2015-0307. Epub 2016 Feb 10.

16.

The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.

Wang K, Shen T, Siegal GP, Wei S.

Hum Pathol. 2017 Nov;69:110-117. doi: 10.1016/j.humpath.2017.09.012. Epub 2017 Oct 6.

PMID:
28993275
17.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
18.

Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.

Liu S, Duan X, Xu L, Xin L, Cheng Y, Liu Q, Ye J, Zhang S, Zhang H, Zhu S, Li T, Liu Y.

Breast Cancer Res Treat. 2015 Nov;154(2):239-49. doi: 10.1007/s10549-015-3617-7. Epub 2015 Oct 26.

PMID:
26498019
19.

[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].

Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Chinese.

PMID:
23291072
20.

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.

Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y, Ohi Y.

Breast Cancer Res Treat. 2016 Jul;158(1):1-9. doi: 10.1007/s10549-016-3848-2. Epub 2016 Jun 3.

Supplemental Content

Support Center